In the United States, attempts to control hospital-acquired (“nosocomial”) infections are proving ineffective, according to the Government Accountability Office (GAO).  In fact, hospital-acquired infections are estimated to be one of the top-ten causes of death in the U.S., claiming 90,000 lives every year.   In this episode, we look at how Dijon Hospital in Dijon, France, is protecting its most vulnerable patients with a new mobile infection control technology from AirInSpace.  The company’s device, called PlasmairT2006, was recently cleared by the FDA to be used in U.S. hospitals.  At Dijon Hospital, there are 40 mobile Plasmair™ units being used in the pediatric and adult haematology wards, where immunocompromised cancer patients are at high risk from deadly airborne pathogens such as aspergillosis.  We speak with two doctors at Dijon Hospital: Dr. Denis Caillot, head of Clinical Haematology, and his colleague, Dr. Ludwig Aho, head of Hospital Hygiene and Epidemiology.